Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

American Journal of Surgical Pathology

Volumn 37, Issue 1, 2013, Pages 61-65

  Long, Georgina V ^a,b   Wilmott, James S ^a   Capper, David ^c,d   Preusser, Matthias ^c,e   Zhang, Yuxiao E ^a   Thompson, John F ^a,f   Kefford, Richard F ^a,b   Von Deimling, Andreas ^c,d   Scolyer, Richard A ^a,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

BRAF; BRAF inhibitor; BRAF mutation; human melanoma; immunohistochemistry; mutation testing; personalized medicine; targeted therapies; V600E; V600K

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; CANCER STAGING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ANTIBODIES, MONOCLONAL; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871619722     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826485c0     Document Type: Article

References (24)

1. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2011;104:392-398.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
3. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1, 320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121:397-405.
4. Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2011. (in press).
5. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
6. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21:2396-2402.
7. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466-474.
8. Elisei R, Ugolini C, Viola D, et al. BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93: 3943-3949.
9. O'Neill CJ, Bullock M, Chou A, et al. BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148:1139-1146.
10. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
11. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012. (in press).
12. Pinzani P, Santucci C, Mancini I, et al. BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta. 2011;412:901-905.
13. Oldenburg RP, Liu MS, Kolodney MS. Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol. 2007;128:398-402.
14. Busby K, Morris A. Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay. J Clin Pathol. 2005;58:372-375.
15. Jarry A, Masson D, Cassagnau E, et al. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes. 2004;18:349-352.
16. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67:2632-2642.
17. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn. 2007;9:464-471.
18. Balch CM, Gershenwald JE, Soong S-j, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27:6199-6206.
19. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122: 11-19.
20. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893-1901.
21. Capper D, Berghoff A, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123: 223-233.
22. Rubinstein J, Sznol M, Pavlick A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67-70.
23. Lin J, Goto Y, Murata H, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer. 2011;104:464-468.
24. Lin J, Takata M, Murata H, et al. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst. 2009;101: 1423-1427.